Mereo BioPharma vs Silence Therapeutics
MREO and SLN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MREO and SLN compare
Silence Therapeutics scores higher on the StockData Score (7 against 1 for Mereo BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MREO | SLN |
|---|---|---|
| Size and price | ||
| Market cap | $219M | – |
| Share price | $0.275 | $19.80 |
| Change, 1 year | −84.6% | 190% |
| Change, 5 years | −85.6% | −10.0% |
| Beta (5Y) | 2.29 | 0.81 |
| Employees | 39 | 88 |
| StockData Score | ||
| Total score | 1 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 9.2× | – |
| FCF yield | −10.1% | – |
| Growth | ||
| Revenue growth (TTM) | – | −98.2% |
| Profitability | ||
| Gross margin | – | 95.0% |
| Operating margin | – | −12344% |
| Net margin | – | −11277% |
| FCF margin | – | −9682% |
| Return on equity | −76.6% | −35.6% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −440.6× | – |
| Current ratio | 5.22 | 23.94 (better) |
| Altman Z-score | −4.68 | – |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 7.1% | 16.6% |
| Held by insiders | 0.18% | 48.1% |
Go deeper
- MREO stock overview
- MREO income statement
- MREO valuation and score
- SLN stock overview
- SLN income statement
- SLN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.